Sublingual Immunotherapy for Japanese Cedar Pollinosis: Current Clinical and Research Status

The incidence of Japanese cedar pollinosis is increasing significantly in Japan, and a recent survey suggested that about 40% of the population will develop this disease. However, spontaneous remission is rare. The increased incident rate of Japanese cedar pollinosis is a huge issue in Japan. Allerg...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakurai, Daiju, Ishii, Hiroki, Shimamura, Ayumi, Watanabe, Daisuke, Yonaga, Takaaki, Matsuoka, Tomokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697594/
https://www.ncbi.nlm.nih.gov/pubmed/36365064
http://dx.doi.org/10.3390/pathogens11111313
_version_ 1784838603787993088
author Sakurai, Daiju
Ishii, Hiroki
Shimamura, Ayumi
Watanabe, Daisuke
Yonaga, Takaaki
Matsuoka, Tomokazu
author_facet Sakurai, Daiju
Ishii, Hiroki
Shimamura, Ayumi
Watanabe, Daisuke
Yonaga, Takaaki
Matsuoka, Tomokazu
author_sort Sakurai, Daiju
collection PubMed
description The incidence of Japanese cedar pollinosis is increasing significantly in Japan, and a recent survey suggested that about 40% of the population will develop this disease. However, spontaneous remission is rare. The increased incident rate of Japanese cedar pollinosis is a huge issue in Japan. Allergen immunotherapy is the only fundamental treatment that modifies the natural course of allergic rhinitis and provides long-term remission that cannot be induced by general drug therapy. Sublingual immunotherapy for Japanese cedar pollinosis has been developed and has been covered by health insurance since 2014 in Japan. The indication for children was expanded in 2018. Clinical trials of sublingual immunotherapy for Japanese cedar pollinosis have demonstrated its long-term efficacy and safety. It is recommended for patients who wish to undergo fundamental treatment regardless of the severity of the practical guidelines for the management of allergic rhinitis in Japan. For sublingual immunotherapy, a long-term treatment period of 3 years or longer is recommended to obtain stable therapeutic effects. In recent years, evidence based on basic research and clinical trials has demonstrated sublingual immunotherapy-induced immunological changes and efficacy in patients; however, biomarkers that objectively predict and judge these therapeutic effects need to be established.
format Online
Article
Text
id pubmed-9697594
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96975942022-11-26 Sublingual Immunotherapy for Japanese Cedar Pollinosis: Current Clinical and Research Status Sakurai, Daiju Ishii, Hiroki Shimamura, Ayumi Watanabe, Daisuke Yonaga, Takaaki Matsuoka, Tomokazu Pathogens Review The incidence of Japanese cedar pollinosis is increasing significantly in Japan, and a recent survey suggested that about 40% of the population will develop this disease. However, spontaneous remission is rare. The increased incident rate of Japanese cedar pollinosis is a huge issue in Japan. Allergen immunotherapy is the only fundamental treatment that modifies the natural course of allergic rhinitis and provides long-term remission that cannot be induced by general drug therapy. Sublingual immunotherapy for Japanese cedar pollinosis has been developed and has been covered by health insurance since 2014 in Japan. The indication for children was expanded in 2018. Clinical trials of sublingual immunotherapy for Japanese cedar pollinosis have demonstrated its long-term efficacy and safety. It is recommended for patients who wish to undergo fundamental treatment regardless of the severity of the practical guidelines for the management of allergic rhinitis in Japan. For sublingual immunotherapy, a long-term treatment period of 3 years or longer is recommended to obtain stable therapeutic effects. In recent years, evidence based on basic research and clinical trials has demonstrated sublingual immunotherapy-induced immunological changes and efficacy in patients; however, biomarkers that objectively predict and judge these therapeutic effects need to be established. MDPI 2022-11-09 /pmc/articles/PMC9697594/ /pubmed/36365064 http://dx.doi.org/10.3390/pathogens11111313 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sakurai, Daiju
Ishii, Hiroki
Shimamura, Ayumi
Watanabe, Daisuke
Yonaga, Takaaki
Matsuoka, Tomokazu
Sublingual Immunotherapy for Japanese Cedar Pollinosis: Current Clinical and Research Status
title Sublingual Immunotherapy for Japanese Cedar Pollinosis: Current Clinical and Research Status
title_full Sublingual Immunotherapy for Japanese Cedar Pollinosis: Current Clinical and Research Status
title_fullStr Sublingual Immunotherapy for Japanese Cedar Pollinosis: Current Clinical and Research Status
title_full_unstemmed Sublingual Immunotherapy for Japanese Cedar Pollinosis: Current Clinical and Research Status
title_short Sublingual Immunotherapy for Japanese Cedar Pollinosis: Current Clinical and Research Status
title_sort sublingual immunotherapy for japanese cedar pollinosis: current clinical and research status
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697594/
https://www.ncbi.nlm.nih.gov/pubmed/36365064
http://dx.doi.org/10.3390/pathogens11111313
work_keys_str_mv AT sakuraidaiju sublingualimmunotherapyforjapanesecedarpollinosiscurrentclinicalandresearchstatus
AT ishiihiroki sublingualimmunotherapyforjapanesecedarpollinosiscurrentclinicalandresearchstatus
AT shimamuraayumi sublingualimmunotherapyforjapanesecedarpollinosiscurrentclinicalandresearchstatus
AT watanabedaisuke sublingualimmunotherapyforjapanesecedarpollinosiscurrentclinicalandresearchstatus
AT yonagatakaaki sublingualimmunotherapyforjapanesecedarpollinosiscurrentclinicalandresearchstatus
AT matsuokatomokazu sublingualimmunotherapyforjapanesecedarpollinosiscurrentclinicalandresearchstatus